Novasep, a service and technology supplier for the life sciences industry, has announced a €6.1m ($7.28m) investment on its Mourenx site in France. This investment will modernise its API manufacturing facility, and reinforce its competitiveness in its markets, worldwide.
The investment includes the installation of equipment and the revamping of cleanrooms for API isolation. This project is aimed to enhance the company’s flexibility and increase capacity for the custom manufacturing of therapeutic molecules, in accordance with safety requirements and improved environmental protection. To accompany the expansion, the company will be creating seven full-time jobs on this site.
This project has been selected as part of the French government’s France Relance recovery plan. Novasep will be supported within the framework of the “Investments for the Future” program, designed to reward innovative and promising industrial investments, with the aim of helping France to increase its economic growth and employment potential.
“This investment sends a strong signal to our customers and partners by increasing our market competitiveness. It further supports our strategy of reinforcing our high-quality offer for the commercial production of innovative therapies. I am proud of this investment which contributes to manufacturing jobs in France and allows us to further develop our activity in the Aquitaine region” says Dr Michel Spagnol, Chairman and CEO of Novasep.
